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a  b  s  t  r  a  c  t
The  pathogenesis  of frailty  and  the  role of  inﬂammation  is poorly  understood.  We  examined  the  evi-
dence  considering  the  relationship  between  inﬂammation  and  frailty  through  a systematic  review and
meta-analysis.  A systematic  literature  search  of  papers  providing  data  on inﬂammatory  biomarkers  and
frailty was carried  out  in major  electronic  databases  from  inception  until May  2016.  From  1856  ini-
tial  hits,  35  studies  (32  cross-sectional  studies  n = 3232  frail,  n  = 11,483  pre-frail  and  n  =  8522  robust,
and  563  pre-frail  + robust;  3 longitudinal  studies  n =  3402  participants  without  frailty  at baseline)  were
meta-analyzed.  Cross-sectional  studies  reported  that  compared  to  6757  robust  participants,  both  1698
frail  (SMD  =  1.00,  95%CI:  0.40–1.61)  and  8568  pre-frail  (SMD  = 0.33,  95%CI:  0.04–0.62)  participants  had
signiﬁcantly  higher  levels  of  C-reactive  protein  (CRP).  Frailty  (n  =  1057;  SMD = 1.12,  95%CI:  0.27–2.13)
and  pre-frailty  (n =  4467;  SMD  = 0.56,  95%CI:  0.00–1.11)  were  associated  with  higher  serum  levels  of
interleukin-6  compared  to  people  who  were  robust  (n = 2392).  Frailty  and  pre-frailty  were  also  signiﬁ-
cantly  associated  with  elevated  white  blood  cell  and  ﬁbrinogen  levels.  In  three  longitudinal  studies,  higher
∗ Corresponding author at: University of Padova, Department of Medicine (DIMED)-Geriatrics Section, Via Giustiniani, 2, 35128 Padova, Italy.
E-mail  address: ilmannato@gmail.com (N. Veronese).
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1568-1637/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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serum  CRP  (OR  = 1.06,  95%CI:  0.78–1.44,)  and  IL-6  (OR  =  1.19,  95%CI:  0.87–1.62)  were  not  associated  with
frailty.  In conclusion,  frailty  and  pre-frailty  are  associated  with  higher  inﬂammatory  parameters  and  in
particular  CRP and  IL-6.  Further  longitudinal  studies  are  needed.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Age-associated decline in reserve and function may  result in a
reduced ability to cope with acute or external stressors faced every
day, which is typically deﬁned as frailty (Clegg et al., 2013). Frailty is
a relevant issue in geriatric medicine, since frailty is associated with
a higher risk of poor outcomes such as falls, depression, disability,
and mortality (Fried et al., 2001). Frailty is becoming one of the
most signiﬁcant clinical conditions affecting older people, with a
prevalence of 10% for those older than 65 years and 30% for those
older than 80 years (Fried et al., 2001).
Despite an increase in interest in frailty, the pathophysiological
changes underlying and preceding frailty are not clearly known.
Inﬂammation is one such potential pathophysiological change
which may  be closely linked with frailty (Chen et al., 2014). Pro-
inﬂammatory cytokines may  inﬂuence frailty either directly by
promoting protein degradation, or indirectly by affecting impor-
tant metabolic pathways (Lang et al., 2009). A direct association
between frailty and elevated levels of inﬂammation, as marked by
elevated interleukin-6 (IL-6), C-reactive protein (CRP), ﬁbrinogen,
and factor VIII, independent of common chronic disease states has
been observed (Newman et al., 2001). Conversely, other studies
have found that these markers are not predictive of incident frailty
in the elderly (Yao et al., 2011). Thus, there is a lack of clarity consid-
ering the role and status of inﬂammation in frailty and to the best
of our knowledge, no meta-analysis has attempted to synthesize
the available data on this topic.
Therefore, we conducted a systematic review and meta-analysis
comparing the inﬂammatory proﬁle of frail and pre-frail with and
robust subjects in cross sectional studies. In addition, we  inves-
tigated whether or not any inﬂammatory parameters at baseline
could predict the onset of frailty in prospective studies. Our hypoth-
esis was that both frailty and pre-frailty were associated with
higher pro-inﬂammatory cytokines levels.
2. Materials and methods
This systematic review was  conducted according to the
Strengthening the Reporting of Observational Studies in Epi-
demiology [STROBE] criteria (von Elm et al., 2008) and the
recommendations in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses [PRISMA] statement (Liberati et al.,
2009). This work followed a pre-determined, but unpublished pro-
tocol available upon request.
2.1. Search strategy
Three independent authors (PS, BS and NV) searched Medline
(via Ovid), Psychinfo and EMBASE for studies from inception until
05/2016 without language restrictions. The search terms used were
(frailty OR frail) AND ((“inﬂammation”[MeSH Terms] OR “inﬂam-
mation”[All Fields]) OR inﬂammatory[All Fields] OR IFN [All Fields]
OR (“interferons”[MeSH Terms] OR “interferons”[All Fields] OR
“interferon”[All Fields]) OR TNF [All Fields] OR “tumor necrosis
factor”[All Fields] OR IL[All Fields] OR “interleukin”[All Fields] OR
“TGF”[All Fields] OR (“apoptosis”[MeSH Terms] OR “apoptosis”[All
Fields]) OR apoptotic[All Fields] OR antiapoptotic [All Fields] OR
CRP[All Fields] OR (“cytokines”[MeSH Terms] OR  “cytokines”[All
Fields] OR “cytokine”[All Fields])).
2.2. Study selection
Included studies were those that were published quantitative
studies of a cross sectional or longitudinal design that (1) reported
on serum levels of inﬂammatory parameters, (2) used a validated
and standardized method for assessing frailty, (3) included a con-
trol group (pre-frail and robust as separated entities or together):
(4) used serum inﬂammatory parameters as predictors of frailty
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(longitudinal design). Studies were excluded if they (1) did not use
a clear diagnostic criteria for frailty or used only one item for its
diagnosis (e.g. low gait speed), (2) measured only in vitro param-
eters, (3) did not measure or did not report quantitative cytokine
levels.
2.3. Data extraction
To be included in the quantitative analyses, we required data on
serum inﬂammatory parameters in frail, pre-frail and robust par-
ticipants expressed as means ± standard deviation (SD) or median
with range (or interquartile range).
Two authors (PS, NV) independently extracted data from the
selected studies in a standardized Microsoft Excel spreadsheet.
Any disagreement was resolved by through discussion with a third
author (BS). The following information was extracted: (i) charac-
teristics of the study population (e.g. sample size, demographics,
country in which the study was performed); (ii) setting in which
the study was performed; (iii) diagnostic criteria for frailty; (iv)
inﬂammatory parameters assessed with correspondent method of
measurement; (v) demographic characteristics (mean age and per-
centage of women) and mean body mass index (BMI) by frailty
status; (v) categorization used for dividing the sample in groups by
serum inﬂammatory levels (for longitudinal studies); (vi) type and
number of adjustments in the multivariate analyses (for longitudi-
nal studies); (vi) follow-up period (only for longitudinal studies).
When information on frailty and/or serum inﬂammatory param-
eters was missing, study authors were contacted to obtain
unpublished data at least 4 times in a one month period.
2.4. Outcomes
The primary outcomes were the serum levels of inﬂammatory
cytokines and parameters in frail vs. pre-frail and robust (as sepa-
rate entities) or vs. pre-frail/robust (as only one group). For incident
frailty, the odds ratios (ORs) adjusted for the highest number of
covariates available, were considered to assess the association
between serum inﬂammatory parameters and frailty and consid-
ered as secondary outcome of our work.
2.5. Assessment of study quality
Study quality was assessed by two investigators (PS, PL), whilst a
third reviewer was available for mediation (NV). For cross-sectional
and longitudinal studies, the Newcastle-Ottawa Scale (NOS) (Wells
et al., 2012) was used to assess study quality. The NOS assigns a
maximum of 9 points based on three quality parameters: selection,
comparability, and outcome (Wells et al., 2012).
2.6. Statistical analysis
Analyses were performed by two independent investigators
(NV, EC) using Comprehensive Meta-Analysis (CMA) 3 (http://
www.meta-analysis.com). All cytokines were meta-analyzed when
≥3 studies contributed data.
In primary analyses, standardized mean differences (SMDs) and
95% conﬁdence intervals (CI) were calculated. In the secondary
analyses, the most adjusted pooled HRs were calculated for longitu-
dinal analyses. When combining studies, the random effects model
was used to account for anticipated heterogeneity (DerSimonian
and Laird, 1986).
Heterogeneity was measured using the chi-squared and I-
squared statistics, assuming that a p ≤ 0.10 for the former and
a value ≥50% for the latter indicated a signiﬁcant heterogeneity
(Higgins and Thompson, 2002).
Given signiﬁcant heterogeneity, a meta-regression analysis was
performed using differences in mean age, body mass index (BMI)
and percentage of females among groups (frail, pre-frail, robust)
as moderators. Moreover, a sensitivity analysis was conducted
stratiﬁed by continent in which the study was  performed (North
America, Asia, Europe), setting (community-dwelling vs. hospital),
and deﬁnition of frailty (Fried’s criteria vs. other deﬁnitions).
Publication bias was assessed by visually inspecting funnel plots
and using the Begg-Mazumdar Kendall tau (Begg and Mazumdar,
1994) and the Egger bias test (Egger et al., 1997). To account for
publication bias, we used the trim-and-ﬁll method, based on the
assumption that the effect sizes of all the studies are normally
distributed around the center of a funnel plot; in the event of asym-
metries, it adjusts for the potential effect of unpublished studies
(Egger et al., 1997). Finally, the fail safe number of negative studies
that would be required to nullify (i.e. make p > 0.05) the effect size
was calculated (Rosenthal, 1979).
3. Results
The search identiﬁed 1856 non-duplicated potentially eligible
studies. After excluding papers following a review of titles and
abstracts (mainly being reviews or not related to the association
between frailty and inﬂammation, full details summarized in Sup-
plementary Fig. 1), 66 full-text articles were examined, and 35
studies (32 cross-sectional (Addison et al., 2014; Almeida et al.,
2012; Arts et al., 2015; Barzilay et al., 2007; Brouwers et al., 2015;
Carcaillon et al., 2012; Chao et al., 2015; Collerton et al., 2012;
Comptè et al., 2013; Darvin et al., 2014; Fontana et al., 2013; Gale
et al., 2013; Hubbard et al., 2009; Hwang et al., 2015; Kalyani et al.,
2012; Lai et al., 2014; Leng et al., 2011, 2007, 2004a,b; Liu et al.,
2016; Piggott et al., 2015; Pustavoitau et al., 2016; Qu et al., 2009;
Rønning et al., 2010; Saum et al., 2015; Sergi et al., 2015; Serviddio
et al., 2009; Singer et al., 2015; Tsai et al., 2013; Walston et al.,
2002; Wu et al., 2009) and 3 longitudinal (Baylis et al., 2013; Puts
et al., 2005; Reiner et al., 2009)) were included in our meta-analysis
(Supplementary Fig. 1).
3.1. Study and patient characteristics
Study and patient characteristics of cross-sectional studies are
summarized in Supplementary Table 1.
The 32 cross-sectional studies (Addison et al., 2014; Almeida
et al., 2012; Arts et al., 2015; Barzilay et al., 2007; Brouwers et al.,
2015; Carcaillon et al., 2012; Chao et al., 2015; Collerton et al., 2012;
Comptè et al., 2013; Darvin et al., 2014; Fontana et al., 2013; Gale
et al., 2013; Hubbard et al., 2009; Hwang et al., 2015; Kalyani et al.,
2012; Lai et al., 2014; Leng et al., 2011, 2007, 2004a,b; Liu et al.,
2016; Piggott et al., 2015; Pustavoitau et al., 2016; Qu et al., 2009;
Rønning et al., 2010; Saum et al., 2015; Sergi et al., 2015; Serviddio
et al., 2009; Singer et al., 2015; Tsai et al., 2013; Wu  et al., 2009)
included a total of 23,910 older participants with a mean age of
75.2 ± 6.1 years.
Overall, there were 3332 (=13.9%) frail, 11,483 pre-frail (=48.0%)
and 8532 robust subjects, while 563 additional participants were
classiﬁed as pre-frail/robust.
All of the included studies used a modiﬁed version of Fried et al.
(2001) deﬁnition for frailty, except for ﬁve deﬁned by Frail Scale,
Balducci Score, Modiﬁed Physical Performance Test Score, Identiﬁ-
cation of Seniors At Risk, MPI  (Addison et al., 2014; Brouwers et al.,
2015; Chao et al., 2015; Comptè et al., 2013; Fontana et al., 2013).
The majority of the studies were conducted among community-
dwellers (22 studies; = 69%) and in North America (n = 14), followed
by Europe (n = 11), Asia (n = 6) and Oceania (n = 1) (Supplementary
Table 1). The quality of the studies, assessed through NOS, was gen-
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erally good with a median = 7 (range: 4–9) (Supplementary Table
1).
Frail participants were older (mean age: 78.1 years), more fre-
quently females (=61.8%) and with higher BMI  (=26.8 kg/m2) than
pre-frail (age: 75.4 years; % of females: 58.9; BMI: 26.4 kg/m2),
robust (age: 72.8 years; % of females: 54.6; BMI: 26.3 kg/m2) or pre-
frail/robust (age: 74.8 years; % of females: 58.9; BMI: 25.8 kg/m2)
participants (Supplementary Table 1).
3.2. Cross-sectional meta-analysis ﬁndings
As reported in Table 1, 13 studies (Barzilay et al., 2007; Carcaillon
et al., 2012; Collerton et al., 2012; Fontana et al., 2013; Hubbard
et al., 2009; Hwang et al., 2015; Lai et al., 2014; Liu et al., 2016;
Rønning et al., 2010; Saum et al., 2015; Tsai et al., 2013; Walston
et al., 2002; Wu et al., 2009) reported that both frail (SMD = 1.00,
95%CI: 0.40–1.61, p < 0.0001; I2 = 98%) and pre-frail (SMD = 0.33,
95%CI: 0.04–0.62, p = 0.03; I2 = 98%) participants had signiﬁcantly
higher serum levels of CRP. The fail safe number of studies (i.e.,
the number of negative studies required to nullify our result >0.05)
was very high for each of these analyses (see Table 1). Similar ﬁnd-
ings emerged when comparing frail vs. pre-frail/robust subjects in
4 studies (Almeida et al., 2012; Arts et al., 2015; Comptè et al., 2013;
Gale et al., 2013) (SMD = 0.25, 95%CI: 0.02–-0.49, p = 0.04; I2 = 81%).
Frailty (SMD = 1.12, 95%CI: 0.27–2.13, p = 0.01; I2 = 99%) and
pre-frailty (SMD = 0.56, 95%CI: 0.00–1.11, p = 0.05; I2 = 99%) were
associated with higher serum levels of IL-6 versus robust partici-
pants. The fail safe number of studies was 1650 and 1014 for the
frailty and pre-frailty analyses, respectively.
Similar results were evident regarding white blood cells and
ﬁbrinogen levels, while no differences emerged for TNF-alpha
(Table 1).
3.3. Meta-regression and sensitivity analyses
Since the differences in inﬂammatory parameters between
frailty, pre-frailty and robustness were characterized by a high
heterogeneity (I2 ≥ 50%, p < 0.05), where a sufﬁcient number of
studies were available (at least 4 for each outcome), we  ran a meta-
regression analysis to seek potential moderators.
As shown in Supplementary 2, very few moderators appeared
to explain the heterogeneity present in our analyses. Differences
in age between the frail and robust samples moderated the results
in the comparison between frail vs. pre-frail/robust regarding CRP
(beta = −0.08; 95%CI: −0.11 to −0.04, p = 0.0003, R2 = 1.00) and
IL-6 (beta = −0.24; 95%CI: −0.40 to −0.08, p = 0.004, R2 = 0.82),
while higher differences in BMI  between frail (beta = 0.97; 95%CI:
0.46–1.49, p = 0.002, R2 = 0.55) or pre-frail (beta = 0.76; 95%CI:
0.18–1.35, p = 0.01, R2 = 0.39) vs. robust participants moderated the
results regarding CRP (Supplementary Table 2).
Supplementary Table 3 shows the results of cross-sectional
studies according to some strata, namely country in which the
study was performed, the setting and the deﬁnition of frailty. Over-
all, these moderators seem not to signiﬁcantly affect our ﬁndings.
In particular, we found that frailty and pre-frailty were associ-
ated with signiﬁcantly elevated CRP and IL-6 levels across all
geographical settings and among community and institutionalized
participants (see Supplementary Table 3).
3.4. Longitudinal meta-analysis ﬁndings
Three studies (Baylis et al., 2013; Puts et al., 2005; Reiner et al.,
2009) followed-up 3402 older participants without frailty at base-
line for a median of 3 years (range: 3–10) (Supplementary Table
4). Ta
b
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Fig. 1. Relationship between serum C-reactive protein levels (a) and interleukin 6 (b) at baseline and incident frailty, adjusted for potential confounders.
After adjusting for a median of 9 potential confounders (range:
7–10), both higher serum CRP (OR = 1.06, 95%CI: 0.78–1.44, p = 0.69,
I20%; Fig. 1a) and IL-6 (OR = 1.19, 95%CI: 0.87–1.62, p = 0.27, I20%;
Fig. 1b) levels were not associated with higher risk of frailty.
3.5. Publication bias
Judging from a visual inspection of funnel plots and using Egger’s
test (Table 1 for cross-sectional studies), no publication bias was
evident for all the outcomes included. A similar absence of publi-
cation bias was present for longitudinal studies, although limited
by the number of studies included.
4. Discussion
In this meta-analysis including 32 cross-sectional studies and
23,910 older subjects, we observed that frailty and pre-frailty were
associated with signiﬁcantly higher serum inﬂammatory param-
eters compared to robust participants. In particular, we found a
large increase in CRP and IL-6 in frail and pre-frail participants
versus robust participants, with very high fail safe number of stud-
ies required to nullify these results. The elevated CRP and IL-6
were consistent across geographical regions and both in commu-
nity and hospital settings. We  also found evidence of elevated white
bloods cells and ﬁbrinogen. On the contrary, three large prospective
studies failed to ﬁnd any association between higher inﬂammatory
levels at baseline and incident frailty. Meta-regression analyses of
the cross-sectional data suggest that age and BMI  moderate the
relationship between CRP and frailty.
The relationship between inﬂammation and frailty is complex
since both linearly increase with advancing old age. Both higher
inﬂammatory levels and frailty are associated with several nega-
tive outcomes in the elderly, like higher mortality, hospitalization
rate and co-morbidity onset (Piggott et al., 2015; Sergi et al., 2015;
Zunszain et al., 2013). In cross-sectional studies, the association of
frailty with higher inﬂammation appears to be consistent since both
frail and pre-frail participants showed signiﬁcant higher serum
levels of CRP, TNF-a, IL-6, white blood cells and ﬁbrinogen. Sev-
eral reasons could explain these results. First, frail and pre-frail
participants have a higher presence of concomitant factors like dis-
ability, medical conditions that could increase the inﬂammatory
parameters. Second, as conﬁrmed by our analyses, frail and pre-frail
people (particularly if community-dwelling) are generally more
obese than robust participants, and obesity signiﬁcantly increases
inﬂammatory parameters (Greenberg and Obin, 2006; Solmi et al.,
2015; Veronese et al., 2015). This hypothesis is also in line with the
increase in adiposity observed in frail subjects that seems to affect
also muscular mass (Addison et al., 2014) and indirectly conﬁrmed
by our meta-regression analysis showing that higher differences
in BMI  between frail or pre-frail vs. robust participants moderated
the results regarding serum CRP concentrations. Finally, frail people
seem to have a signiﬁcant reduction in innate immune system, T-
cell activity, antibodies production and increase in mitochondrial
activity with an increase in oxidative stress products, ultimately
leading to an increase in serum inﬂammatory levels (Hubbard and
Woodhouse, 2010; Li et al., 2011).
Conversely, the analyses from our longitudinal studies did not
show any association between higher inﬂammatory levels and the
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onset of frailty. The lack of relationship might be due to the paucity
of data, however, it may  well also indicate that these inﬂammatory
markers are not associated with a predisposition for developing
frailty and may  arise once frailty has set int. Another hypothe-
sis is that the longitudinal studies included in our meta-analysis
included a median of 9 baseline potential confounders. Therefore,
an over-adjustment of the analyses could not to be excluded. The
absence of an univocal operational deﬁnition for frailty, in fact,
makes the development of measurable biomarkers particularly
important (Calvani et al., 2015) and if higher inﬂammatory param-
eters are able to predict the onset of frailty could be of importance
since they are largely diffused worldwide and since higher inﬂam-
matory parameters probably contribute to transitions from frailty
to disability and other negative outcomes (Zaslavsky et al., 2013).
A possible hypothesis for this lack of association is that frail peo-
ple are very sensitive to acute and sub-acute diseases that might
increase inﬂammatory parameters during follow-up period and
none of the studies included adjusted their analyses for inher-
ent changes in these markers. Clearly, future studies including
these adjustments are needed to better investigate the poten-
tial role of inﬂammatory parameters in predicting frailty in the
elderly.
The meta-regression analyses identiﬁed some characteristics
of frail and pre-frail participants compared to robust subjects
could explain the differences in inﬂammatory parameters seen.
In particular, differences in age and BMI  moderated the results
in the comparison between frail vs. pre-frail/robust regarding
CRP and IL-6 suggesting an important role of these factors in
the higher inﬂammatory levels found in these subjects com-
pared to robust ones. On the contrary, the deﬁnition of frailty
did not affect our ﬁndings suggest that, independently from the
deﬁnition used, frail people are characterized by a metabolic sig-
nature in which inﬂammation plays a relevant role (Fontana et al.,
2013).
The ﬁndings of our study should be interpreted within its lim-
itations. First, we encountered moderate-high heterogeneity in
most of the cross-sectional analyses. Whilst the Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) guidelines state
heterogeneity is to be expected when analyzing observational data,
we were only partially able to explain the heterogeneity with meta
regression analysis. Second, almost all the studies used the cri-
teria proposed by Fried et al., but this deﬁnition includes only
physical frailty and does not consider other aspects (for instance
cognitive status), which is of relevance in frailty (Zaslavsky et al.,
2013). The focus on physical frailty is not suitable for people with
advance cognitive decline (e.g. dementia) who may  also be highly
susceptible to frailty. Therefore, future research is also required to
understand frailty (considering cognitive status) and inﬂammation
among people with dementia. Moreover, the frailty phenotype did
not allow to a better understanding of the underlying contribut-
ing factors to frailty and inﬂammation. Third, the categorization
of people as robust/pre-frail/frail other factors (e.g. differences
in comorbidities) may  explain some of the relationship between
physical frailty and inﬂammation. Therefore, future studies using
other deﬁnitions of frailty should attempt to match up frail/pre
frail and robust participants and account for between group differ-
ences in important comorbidities/factors which may  also inﬂuence
inﬂammation. Fourth, all the studies investigating frailty accord-
ing to the deﬁnition of Fried et al. and did not use the original
versions and instead adapted the frailty criteria which can inﬂu-
ence the quality of the composite score and potentially introduce
bias (Theou et al., 2015). Agreement between modiﬁed criteria with
the primary frailty phenotype, in fact, is generally low-moderate.
However, the impact of this on our results is unclear. Finally,
only three longitudinal studies were eligible, with a lack of clar-
ity concerning the results. Therefore, future longitudinal research
is required to disentangle the directionality of the inﬂammation
and frailty relationships we observed in our comprehensive cross
sectional analyses. Nonetheless, our meta-analysis is a ﬁrst and
included a large number of studies included and inﬂammatory out-
comes. The data from our cross sectional results were also free
from publication bias and the results indicating greatly increased
levels of CRP and IL-6 had very large fail safe number of studies
(both >1000).
In conclusion, frailty and pre-frailty are associated with higher
inﬂammatory parameters levels, in particular CRP and IL-6. How-
ever, longitudinal studies did not conﬁrm these ﬁndings, suggesting
that other studies are needed to better understand if these inﬂam-
matory markers could be used as potential biomarkers of frailty in
the elderly.
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